|
covid-19 |
55 |
|
sars-cov-2 |
41 |
|
covid-19 vaccine |
39 |
|
mortality |
31 |
|
primary care |
30 |
|
bnt162b2 |
29 |
|
coronavac |
29 |
|
vaccine safety |
29 |
|
type 2 diabetes mellitus |
28 |
|
covid-19 vaccines |
27 |
|
diabetes mellitus |
22 |
|
complications |
21 |
|
cardiovascular diseases |
19 |
|
chinese |
19 |
|
hypertension |
19 |
|
epidemiology |
18 |
|
inactivated vaccine |
18 |
|
self-controlled case series |
18 |
|
cardiovascular disease |
17 |
|
diabetes |
17 |
|
health-related quality of life |
16 |
|
nomogram |
16 |
|
risk stratification |
16 |
|
stroke |
16 |
|
colorectal cancer |
15 |
|
responsiveness |
15 |
|
vaccine effectiveness |
15 |
|
coronavirus infection |
14 |
|
health outcomes |
14 |
|
heart failure |
14 |
|
blood pressure |
13 |
|
cardiovascular complications |
13 |
|
cardiovascular magnetic resonance |
13 |
|
hemoglobin a1c |
13 |
|
mental health |
13 |
|
microvascular complications |
13 |
|
quality of care |
13 |
|
quality of life |
13 |
|
adverse events |
12 |
|
chronic kidney disease |
12 |
|
cohort study |
12 |
|
innate immunity |
12 |
|
tuberculosis |
12 |
|
type 2 diabetes |
12 |
|
hong kong |
11 |
|
hospitalisation |
11 |
|
omicron |
11 |
|
prediction model |
11 |
|
preventive medicine |
11 |
|
screening |
11 |
|
sf-12 |
11 |
|
variability |
11 |
|
atrial fibrillation |
10 |
|
autoimmune disorders |
10 |
|
bidirectional relationship |
10 |
|
child health |
10 |
|
delirium |
10 |
|
dementia |
10 |
|
incident cvd |
10 |
|
ischemic stroke |
10 |
|
long covid |
10 |
|
low-income families |
10 |
|
major adverse cardiovascular events |
10 |
|
metformin |
10 |
|
parental stress |
10 |
|
pasc |
10 |
|
post-acute sequelae of sars-cov-2 |
10 |
|
post-covid cvd |
10 |
|
prognosis |
10 |
|
sex difference |
10 |
|
adverse events of special interest (aesi) |
9 |
|
cancer |
9 |
|
chest x-ray |
9 |
|
end stage renal disease |
9 |
|
infection |
9 |
|
molnupiravir |
9 |
|
nirmatrelvir-ritonavir |
9 |
|
pediatrics |
9 |
|
pharmacovigilance |
9 |
|
safety |
9 |
|
stress |
9 |
|
vaccine |
9 |
|
viral disease |
9 |
|
waning vaccine effectiveness |
9 |
|
white cell count |
9 |
|
4d flow |
8 |
|
adverse events of special interest |
8 |
|
cohort studies |
8 |
|
direct flow |
8 |
|
hfpef |
8 |
|
intraventricular flow |
8 |
|
management programme |
8 |
|
mrna vaccine |
8 |
|
myocarditis |
8 |
|
odds ratio |
8 |
|
pediatric population |
8 |
|
pericarditis |
8 |
|
residual volume |
8 |
|
risk |
8 |
|
risk assessment |
8 |
|
anchor |
7 |
|
anxiety |
7 |
|
aspirin |
7 |
|
cardiovascular disease risk |
7 |
|
depression |
7 |
|
dialysis patients |
7 |
|
fact-c |
7 |
|
general diabetes |
7 |
|
glycated haemoglobin |
7 |
|
health-related quality of life (hrqol) |
7 |
|
indirect effect |
7 |
|
lower urinary tract symptoms |
7 |
|
management |
7 |
|
mental disorders |
7 |
|
meta-analysis |
7 |
|
multidisciplinary |
7 |
|
myocardial infarction |
7 |
|
nursing |
7 |
|
peritoneal dialysis |
7 |
|
primary health care |
7 |
|
quality in health care |
7 |
|
renal replacement therapy |
7 |
|
short form-12 health survey version 2 (sf-12v2) |
7 |
|
systematic review |
7 |
|
vaccination |
7 |
|
visit‐to‐visit variability |
7 |
|
asymptomatic |
6 |
|
china |
6 |
|
cohort |
6 |
|
continuity of care |
6 |
|
cost-effectiveness |
6 |
|
cvd |
6 |
|
gastroenterology |
6 |
|
gastrointestinal tumours |
6 |
|
haemoglobin a1c |
6 |
|
hdl‐c |
6 |
|
high cardiovascular risk |
6 |
|
intercalation enrichment year |
6 |
|
ldl‐c |
6 |
|
learning experience |
6 |
|
life expectancy |
6 |
|
lipids |
6 |
|
lipids variability |
6 |
|
medical sciences |
6 |
|
mixed-method study |
6 |
|
mortality risk |
6 |
|
non-steroidal anti-inflammatory drugs |
6 |
|
nsaids |
6 |
|
prediction |
6 |
|
prevention |
6 |
|
risk algorithm |
6 |
|
risk factors |
6 |
|
risk prediction |
6 |
|
stress cardiac magnetic resonance |
6 |
|
studiesmortality |
6 |
|
type 2 diabetes mellitus (t2dm) |
6 |
|
undergraduate medicine curriculum |
6 |
|
undiagnosed diabetes |
6 |
|
validation |
6 |
|
volume–outcome |
6 |
|
volume–quality |
6 |
|
adenosine triphosphate |
5 |
|
antibiotics |
5 |
|
antivirals |
5 |
|
chinese medicine;multi-centre |
5 |
|
community centre |
5 |
|
competing risks |
5 |
|
coronary artery disease |
5 |
|
corticosteroids |
5 |
|
costing analysis |
5 |
|
database research |
5 |
|
dating apps |
5 |
|
dialysis |
5 |
|
enalapril |
5 |
|
endocrinology |
5 |
|
end‐ |
5 |
|
end‐stage renal disease |
5 |
|
fact-p |
5 |
|
follow - up care |
5 |
|
haemodialysis |
5 |
|
health policy |
5 |
|
health related quality of life |
5 |
|
healthcare costs |
5 |
|
hospital |
5 |
|
hypertension (ht) |
5 |
|
instrument |
5 |
|
interferons |
5 |
|
mediation |
5 |
|
medical education & training |
5 |
|
medication safety |
5 |
|
men who have sex with men |
5 |
|
multi-disciplinary |
5 |
|
multidisciplinary-risk-assessment-and-management-programme |
5 |
|
nocturia |
5 |
|
nocturnal home haemodialysis |
5 |
|
orphan drug designation |
5 |
|
patient-reported outcomes |
5 |
|
patient‐reported outcome |
5 |
|
pharmacoepidemiolgy |
5 |
|
physician encounters |
5 |
|
physiology |
5 |
|
population-based cohort |
5 |
|
postmarketing surveillance |
5 |
|
predictors |
5 |
|
prostate cancer |
5 |
|
recurrence |
5 |
|
risk prediction model |
5 |
|
risky sexual behaviours |
5 |
|
risk–benefit trade-off |
5 |
|
sacubitril/valsartan |
5 |
|
self-management |
5 |
|
sexual health |
5 |
|
sf-12v2 |
5 |
|
sleep quality |
5 |
|
stage renal disease |
5 |
|
structured education |
5 |
|
survival |
5 |
|
temporal trend |
5 |
|
young age of onset |
5 |
|
accident and emergency department attendances |
4 |
|
active transport |
4 |
|
acute wound |
4 |
|
asians |
4 |
|
assessment |
4 |
|
bmi |
4 |
|
bodily pain |
4 |
|
chronic wound |
4 |
|
colonoscopy |
4 |
|
conservative treatment |
4 |
|
coronary heart disease |
4 |
|
depressive disorders |
4 |
|
effectiveness |
4 |
|
family medicine |
4 |
|
family practice |
4 |
|
fecal occult blood testing |
4 |
|
general practice |
4 |
|
genetic susceptibility |
4 |
|
good hrqol |
4 |
|
hba1c |
4 |
|
health seeking |
4 |
|
health services research |
4 |
|
hospital admissions |
4 |
|
hrqol data |
4 |
|
hrqol outcome |
4 |
|
hrqol score |
4 |
|
incidence |
4 |
|
incontinence |
4 |
|
instrument development |
4 |
|
macrovascular disease |
4 |
|
mass screening |
4 |
|
microvascular disease |
4 |
|
morbidity |
4 |
|
morbidity survey |
4 |
|
multidisciplinary intervention |
4 |
|
nurse practitioners urology |
4 |
|
outcomes research methods |
4 |
|
outpatient clinics |
4 |
|
patient-reported outcome |
4 |
|
practice-based research |
4 |
|
predictor |
4 |
|
prevalence |
4 |
|
psychometric testing |
4 |
|
quality of life (qol) |
4 |
|
ramp-dm |
4 |
|
risk assessment and management |
4 |
|
risk factor |
4 |
|
risk management |
4 |
|
substance use disorders |
4 |
|
trajectory |
4 |
|
type 2 diabetes, structured education |
4 |
|
uk biobank |
4 |
|
urology |
4 |
|
wound assessment |
4 |
|
action research |
3 |
|
addqol-19 |
3 |
|
all-cause mortality |
3 |
|
audit |
3 |
|
bother |
3 |
|
cardiovascular events |
3 |
|
delivery of care |
3 |
|
depressive disorder |
3 |
|
diabetes care |
3 |
|
eortc qlq-c30 |
3 |
|
estimated glomerular filtration rate (egfr) |
3 |
|
health personnel |
3 |
|
health service |
3 |
|
health status |
3 |
|
hepatitis c virus (hcv) |
3 |
|
latent class analysis |
3 |
|
linkage-to-care |
3 |
|
mapping |
3 |
|
novel predictor |
3 |
|
patient acceptance of health care |
3 |
|
population-based |
3 |
|
preference-based |
3 |
|
preference-based scores |
3 |
|
sf-6d |
3 |
|
shared care |
3 |
|
statin |
3 |
|
structure of care |
3 |
|
testing |
3 |
|
tree analysis |
3 |
|
urine albumin-to-creatinine ratio (uacr) |
3 |
|
validity |
3 |
|
adult |
2 |
|
anticipated regret |
2 |
|
attitude |
2 |
|
consultation |
2 |
|
coronavirus disease 2019 |
2 |
|
cross-sectional study |
2 |
|
family doctors |
2 |
|
impaired fasting glucose |
2 |
|
intention |
2 |
|
internet |
2 |
|
non-insulin-dependent diabetes - complications |
2 |
|
non-insulin-dependent diabetes - mortality |
2 |
|
pandemic |
2 |
|
preparedness |
2 |
|
self-efficacy |
2 |
|
sleep |
2 |
|
young adult |
2 |
|
atherosclerosis |
1 |
|
carotid intima‐media thickness |
1 |
|
first-ever stroke |
1 |
|
lean body mass |
1 |
